Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression.
Meisam BagheriGadisti Aisha MohamedMohammed AshickMohamed SaleemNevena B OgnjenovicHanxu LuFred W KollingOwen M WilkinsSubhadeep DasIan S La CroixShivashankar H NagarajKristen E MullerScott A GerberTodd W MillerDiwakar R PattabiramanPublished in: bioRxiv : the preprint server for biology (2023)
While the advent of targeted therapy has led to vast improvements in outcomes for certain types of breast cancer, a mainstay for triple-negative breast cancer (TNBC) remains cytotoxic chemotherapy. A major clinical hurdle in successfully managing this disease is the eventual development of therapeutic resistance and disease relapse in more aggressive forms. Our data reveal that epigenetic modulation of EMT state using the FDA-approved therapeutic eribulin curtails metastatic propensity of breast tumors and, when administered in the treatment-naïve setting, sensitizes to subsequent treatment with other chemotherapeutics.
Keyphrases
- squamous cell carcinoma
- breast cancer cells
- stem cells
- gene expression
- type diabetes
- clinical trial
- dna methylation
- bone marrow
- electronic health record
- radiation therapy
- epithelial mesenchymal transition
- skeletal muscle
- adipose tissue
- artificial intelligence
- machine learning
- deep learning
- mouse model
- endoplasmic reticulum stress
- rectal cancer
- data analysis
- double blind
- placebo controlled